RxDoctor Payments Data

Lori Schaffer

Family · du Bois, PANPI 1184167090

Payments from drug & device makers

$10,525in general payments, 2019–2025

Across 538 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • AstraZeneca$671
  • Pfizer$481
  • Otsuka America Pharmaceutical, Inc.$469
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$10,525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk123$1,956
AbbVie71$1,151
Johnson & Johnson29$1,042
AstraZeneca(2 entities)32$671
Pfizer23$481
Otsuka America Pharmaceutical, Inc.20$469
GSK16$360
Novartis18$333
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)14$293
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$293
Amgen(2 entities)17$292
Lilly USA, LLC17$259
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$241
Alnylam Pharmaceuticals Inc.4$210
Exact Sciences10$198
Amarin Pharma, Inc.10$178
Lexicon Pharmaceuticals, Inc.4$165
Astellas Pharma US Inc9$130
Ardelyx, Inc.5$110
Lundbeck LLC5$106
Phathom Pharmaceuticals, Inc.4$98
Sumitomo Pharma America, Inc.5$97
Bayer6$96
Abbott5$93
Xeris Pharmaceuticals, Inc.5$92
Dexcom, Inc.4$84
Sunovion Pharmaceuticals Inc.5$81
Daiichi Sankyo Inc.5$70
Vanda Pharmaceuticals Inc.3$69
Boehringer Ingelheim4$69
Teva Pharmaceuticals USA, Inc.3$54
Acadia Pharmaceuticals Inc2$49
Biohaven Pharmaceutical Holding Company Ltd.3$46
UCB, Inc.2$44
Nestle Healthcare Nutrition Inc.3$40
Sanofi Pasteur Inc.2$40
Inspire Medical Systems, Inc.2$39
E.r. Squibb & Sons, L.L.C.2$37
Merck2$32
Antares Pharma, Inc.1$29
Avanir Pharmaceuticals, Inc.1$29
Kowa Pharmaceuticals America, Inc.2$28
Qiagen, LLC1$28
Sequel Med Tech, LLC1$27
Sonex Health, Inc.1$23
Insulet Corporation1$22
Sun Pharmaceutical Industries Inc.1$21
Biogen1$21
Preventice Services, LLC1$18
Collegium Pharmaceutical, Inc.1$18
Shield Therapeutics Inc1$18
Neurocrine Biosciences, Inc.1$18
Urovant Sciences Inc1$17
Kyowa Kirin, Inc.1$16
Biohaven Pharmaceuticals, Inc.1$14
Esperion Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,525 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,320
Medicare patients
195
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$159,285
EliquisApixaban213$131,799
XareltoRivaroxaban66$58,416
JardianceEmpagliflozin72$55,314
TrulicityDulaglutide39$47,455
Xtampza ErOxycodone Myristate39$37,395
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$34,226
FarxigaDapagliflozin Propanediol50$33,404
MounjaroTirzepatide32$32,450
Nurtec OdtRimegepant Sulfate20$29,935
ZenpepLipase/Protease/Amylase16$22,303
EntrestoSacubitril/Valsartan21$20,228
MyrbetriqMirabegron35$16,510
JanuviaSitagliptin Phosphate19$16,114
LinzessLinaclotide27$14,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,956$171,342161 claims
PfizerEliquis, Nurtec Odt$481$161,734233 claims
Lilly USA, LLCTrulicity, Mounjaro$259$79,90671 claims
Boehringer IngelheimJardiance, Spiriva Respimat$69$65,84491 claims
Johnson & JohnsonXarelto$1,042$58,41666 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$360$54,444103 claims
Collegium Pharmaceutical, Inc.Xtampza Er$18$37,39539 claims
AstraZenecaFarxiga$671$33,40450 claims
NovartisEntresto$333$20,22821 claims
Astellas Pharma US IncMyrbetriq$130$16,51035 claims
MerckJanuvia$32$16,11419 claims
AbbVieLinzess$1,151$14,36227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →